Get the Stockscreener App
28.55
5.78%
1.56
Tyra Biosciences Inc stock is traded at $28.55, with a volume of 987.12K.
It is up +5.78% in the last 24 hours and down -22.92% over the past month.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
See More
Previous Close:
$26.99
Open:
$27.19
24h Volume:
987.12K
Relative Volume:
1.02
Market Cap:
$1.70B
Revenue:
-
Net Income/Loss:
$-131.11M
P/E Ratio:
-13.13
EPS:
-2.1745
Net Cash Flow:
$-102.47M
1W Performance:
+6.73%
1M Performance:
-22.92%
6M Performance:
+29.07%
1Y Performance:
+173.73%
1-Day Range:
$26.58
$28.57
1-Week Range:
$24.66
$28.57
52-Week Range:
$8.98
$40.65
Tyra Biosciences Inc Stock (TYRA) Company Profile
Name
Tyra Biosciences Inc
Sector
Industry
Phone
(619) 728-4760
Address
2656 STATE STREET, CARLSBAD
Compare TYRA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TYRA
Tyra Biosciences Inc
|
28.55 | 1.70B | 0 | -131.11M | -102.47M | -2.1745 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tyra Biosciences Inc Stock (TYRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-26 | Initiated | Guggenheim | Buy |
| Apr-06-26 | Initiated | Canaccord Genuity | Buy |
| Feb-24-26 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-10-26 | Initiated | William Blair | Outperform |
| Jan-28-26 | Initiated | Barclays | Overweight |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| May-21-25 | Resumed | Piper Sandler | Overweight |
| Jan-07-25 | Initiated | UBS | Buy |
| Oct-18-24 | Upgrade | BofA Securities | Neutral → Buy |
| Aug-15-24 | Initiated | Piper Sandler | Overweight |
| Dec-15-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-30-23 | Initiated | Wedbush | Outperform |
| Feb-03-23 | Initiated | Oppenheimer | Outperform |
| Jun-23-22 | Initiated | H.C. Wainwright | Buy |
| Mar-08-22 | Upgrade | Jefferies | Hold → Buy |
| Nov-08-21 | Downgrade | Jefferies | Buy → Hold |
| Oct-11-21 | Initiated | BofA Securities | Buy |
| Oct-11-21 | Initiated | Cowen | Outperform |
| Oct-11-21 | Initiated | Jefferies | Buy |
View All
Tyra Biosciences Inc Stock (TYRA) Latest News
TYRA Q1 2026 Earnings: EPS Miss Amid Pre-Revenue Stage, Stock Gains 5.55%Earnings Seasonality - newsline.com
Tyra Biosciences (TYRA) Surges 5.55% on Strong Volume, Testing Key Resistance LevelsCash Flow Strong Stocks - newsline.com
Is Tyra Biosciences (TYRA) Too Reliant On Dabogratinib Amid Renewed SURF-302 Skepticism? - Yahoo Finance
Urothelial Carcinoma Market on Track for Major Expansion - openPR.com
Urothelial Carcinoma Market on Track for Major Expansion by 2036, According to DelveInsight | Bristol-Myers Squibb, Astellas Pharma, Pfizer, Johnson & Johnson, Pfizer, Tyra Biosciences, Infinity - Barchart.com
BofA Securities Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Raises Target Price to $42 - Moomoo
Tyra Biosciences' Weak Investor Sentiment Reflects Macro Pressures, Renewed SURF-302 Concerns, BofA Says - Moomoo
TYRA Maintains Rating by B of A Securities -- Price Target Raised to $42 - GuruFocus
Tyra Biosciences, Inc. Stock 12‑Month Price Target Cut to $50.8, Implies 96% Upside - TradingView
BofA Securities Raises Price Target on Devon Energy to $42 From $37, Buy Rating Kept - marketscreener.com
BofA raises Tyra Biosciences stock price target on safety outlook By Investing.com - Investing.com Nigeria
Analyst Initiates Buy on Tyra Biosciences, Citing De-Risked Dabogratinib Program and Attractive Entry Ahead of Key Bladder Cancer Data - TipRanks
BofA raises Tyra Biosciences stock price target on safety outlook - Investing.com
TYRA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Tyra Biosciences (TYRA) Declines 1.67% as Stock Tests Key Support LevelsCovered Call Trade - newsline.com
Raymond James reiterates Strong Buy on Tyra Biosciences stock amid recent weakness - Investing.com Canada
TYRA: Dabogratinib advances in three FGFR3-driven indications, with pivotal data readouts ahead - TradingView
Tyra Biosciences Shareholders Reelect Directors and Ratify Auditor - TipRanks
Tyra Biosciences (NASDAQ: TYRA) details 2026 shareholder meeting voting outcomes - Stock Titan
Tyra Biosciences (TYRA) director option grant tied to RA Capital funds - Stock Titan
Tyra Biosciences (TYRA) director awarded 13,160 stock options at $32.68 strike - Stock Titan
Tyra Biosciences (TYRA) director granted 13,160 stock options at $32.68 - Stock Titan
Tyra Biosciences (TYRA) director option grant held for RA Capital funds - Stock Titan
Tyra Biosciences (NASDAQ: TYRA) grants 13,160 stock options to director Adele Gulfo - Stock Titan
Director at Tyra Biosciences (NASDAQ: TYRA) awarded stock options - Stock Titan
Tyra Biosciences (TYRA) director granted 13,160 stock options - Stock Titan
[144] Tyra Biosciences, Inc. SEC Filing - Stock Titan
Tyra Biosciences Expands Precision Oncology Clinical Pipeline - asatunews.co.id
Tyra Biosciences Reports Net Loss and Advances Cancer Drug Strategy - HarianBasis.co
Wolfe Research Initiates Peer Perform rating on Tyra Biosciences, Inc. (TYRA) - Yahoo Finance
TYRA Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Advances Pipeline - newsline.com
Tyra Biosciences (TYRA) Gains 2.23% as Speculative Interest Returns to BiotechKAMA Signal - The Legal Advocate
What's Driving Tyra Biosciences' Recent Surge - Kavout
Tyra Biosciences (TYRA) Advances 2.23% as Stock Closes Near Resistance at $35.08Up Down Ratio - newsline.com
Tyra Biosciences Inc. (TYRA) Faces Modest Decline as Shares Test Key Support ZoneVolume Profile - The Legal Advocate
Tyra Biosciences Inc. (TYRA) Q1 2026 Earnings: Wider-Than-Expected Loss as Clinical Pipeline Progress ContinuesEarnings Quality Analysis - newsline.com
CCORF Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $50 - Moomoo
How Tyra Biosciences Inc. (TYRA) Affects Rotational Strategy Timing - Stock Traders Daily
This Tyra Biosciences Insider Reduced Their Stake By 58% - Moomoo
Tyra Biosciences (TYRA) Surges 3.45% as Biotech Momentum BuildsNHNL Ratio - newsline.com
TYRA Pulls Back: Market Rotation Hits Communication - Newser
Tyra Biosciences, Inc. Stock 12‑Month Price Target Raised to $51.78, Implies 59% Upside - TradingView
William Blair Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating - Moomoo
Tyra Biosciences Stock Has a Data Question Investors Can’t Ignore - Bez Kabli
Tyra Biosciences (TYRA) Slips Slightly as Stock Holds Between Key Support and Resistance LevelsBuffered ETF - The Legal Advocate
TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY - PR Newswire
Tyra Biosciences (TYRA) Q1 2026 Miss: What Went WrongCommunity Buy Signals - Newser
Wolfe Research initiates coverage of Tyra Biosciences (TYRA) with peer perform recommendation - MSN
Tyra Biosciences (TYRA) Q1 2026 Disappoints — EPS $-0.64 Below $-0.60 ViewsAnalyst Consensus Shift - Newser
TYRA Initiates Coverage On Wolfe Research -- Rating Set to Peer Perform - GuruFocus
Wolfe Research initiates Tyra Biosciences stock at Peerperform By Investing.com - Investing.com Canada
Tyra Biosciences Inc Stock (TYRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):